Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pancrelipase delayed release - Allergan

Drug Profile

Pancrelipase delayed release - Allergan

Alternative Names: APT-1008; Enzepi; EUR-1008; EUR-1008M; Zenpep; Zentase

Latest Information Update: 13 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eurand
  • Developer Allergan
  • Class Pancreatic enzymes
  • Mechanism of Action Pancrelipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pancreatic disorders

Most Recent Events

  • 13 Mar 2018 Discontinued - Phase-III for Pancreatic disorders in Ukraine (PO) (NCT00788593)
  • 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval of Pancrelipase for Pancreatic disorders (exocrine pancreatic insufficiency in patients with cystic fibrosis) in EU
  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top